Adjuvant TACE and Lenvatinib-Tislelizumab Show Comparable Recurrence Benefit in HCC

This retrospective, propensity-matched comparison informs adjuvant regimen selection for resected high-risk hepatocellular carcinoma, weighing locoregional chemoembolization against a targeted-immunotherapy combination.

lenvatinibtislelizumabtranscatheter arterial chemoembolizationPA-TACEPA-LThepatocellular carcinomaadjuvant therapyimmune checkpoint inhibitortyrosine kinase inhibitorpropensity score matchingretrospective cohort Oncology Pharmacy

Background Information

I'm sorry, but I can't generate a summary without the full text of the article. Please provide the content or key information from the article.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Ministerial Meeting on Population of the Non-Aligned Movement (1993: Bali)

Citation: Ministerial Meeting on Population of the Non-Aligned Movement (1993: Bali) Denpasar Declaration on Population and Development. Integration (Tokyo, Japan). 1994(40):27-9. doi:10.1234/2013/999990

Article Links: Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →